Dataset opportunity
Eclevar — 医学影像数据集机会
Eclevar 持有的海量医学影像数据集，可用于诊断人工智能和计算机视觉。
Score
42.5
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
63%
Action
数据共享协议
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
全球人工智能驱动的诊断影像市场 = 2024 年为 34.6 亿美元，复合年增长率为 26.40%（来源：AI-Powered Diagnostic Imaging Market Report 2032）。[1]
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
Profile
Dataset profile
Type
医学影像数据集
Modality
图像
Sector
医疗保健
Volume
大型
Freshness
定期
Rarity
中等
Accessibility
受限
Legal
混合所有权 — GDPR 敏感（个人身份信息审查）
Buyer persona
医疗人工智能与诊断影像公司
作为一家专注于欧盟医疗器械法规 (EU MDR) 下医疗器械的临床研究组织 (CRO)，Eclevar 拥有重要的医学影像数据集。该数据集直接来源于临床试验，并与监管文件和病历相关联，为开发、训练和验证强大的诊断人工智能 (AI) 算法提供了高保真度的基础。
全球人工智能驱动的诊断影像市场的价值凸显了其商业价值，该市场在 2024 年的估值为34.6 亿美元，预计将以 26.40% 的复合年增长率 (CAGR) 增长。[1] 尽管由于 GDPR/HIPAA 法规和临床试验协议的限制，数据访问复杂，但该数据集经过精心策划且符合监管要求的高质量，使其成为寻求竞争优势和监管批准的 AI 公司的稀有且重要的资产。⚠ 尽职调查（有价值的数据，可协商的访问权限）：临床数据受严格的 GDPR 和 HIPAA 法规约束；主要数据所有权通常归医疗器械制造商（客户）所有；访问需要处理复杂的临床试验协议和伦理委员会批准。· 公司：独立。
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
这些证据共同证明了持有者 Eclevar 拥有一个持续的高质量、符合监管要求的医疗数据管道，来源于自 2020 年以来进行的 50 多个器械项目。该数据集包含医学影像，是通过符合严格欧盟医疗器械法规 (EU MDR) 的上市后临床调查产生的，并保持着零重大不合规的记录。对于诊断 AI 公司而言，这是一个难得的机会，可以获得已降低风险且合规的数据，以在一个预计每年增长超过 26% 的蓬勃发展的市场中训练和验证算法。
See dimension details ↓- Dataset Specificity78
主导的“病历”，医疗保健行业，2 种特定类型
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity46
专有领域数据（开放会降低稀有度）
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Deep Qualification90
⚠ 需要审查 — Eclevar 是一家服务提供商（CRO），为客户管理临床试验数据；它不拥有这些数据，数据属于医疗器械制造商（申办方），并受严格的 GDPR 法规约束。[数据归公司客户所有]
- Dataset Volume80
5 个证据命中，明确提及数据量
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness62
API/开放（当前）
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value74
适用于诊断 AI
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand95
买家对高质量医学影像数据的需求异常高，这得益于诊断 AI 市场以 26.40% 的复合年增长率增长。[1]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility26
开放/API 访问
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility50
高难度，独立
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength86
5 种证据类型，5 次命中
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License28
所有权=混合，许可=GDPR 敏感
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
独立
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation56
2 个数据需求信号（2 种类型）
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus70
盈余=中等 — 超出已货币化部分的专有数据
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit42
⚠ 审查 — Eclevar 是一家合同研究组织 (CRO)，其核心业务是向医疗器械公司销售临床试验和数据管理服务；它不拥有由此产生的数据，使其成为服务提供商而非理想目标。问题：核心业务是提供数据作为可交付成果（临床试验、数据管理、监管策略）的服务，而不是副产品。[2, 7, 9]；作为 CRO，它代表其客户（申办方）管理数据，申办方保留最终控制权。
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
API access
这表明临床试验使用了结构化的数据管理计划，确保生成的多模态数据可审计且格式化，适合复杂的 AI 模型开发。
Downloads / exports
这表明在欧洲和日本等关键市场拥有成熟的运营业务，表明其数据收集和治理实践符合多项国际监管标准。
Regulatory records
持有者已成功在严格的欧盟医疗器械法规 (EU MDR) 下交付了 50 多个器械项目，证明了来自上市后临床调查的稳定且可扩展的符合监管要求的数据来源。
Medical records / imaging
作为一家专业的临床研究组织，该公司直接从上市后临床调查 (PMCF) 中生成影像数据，提供了用于训练诊断 AI 的高度追捧的真实世界证据。
Data-volume signal
这展示了卓越的数据质量和合规性，在提交给公告机构的报告中零重大不合规，对于需要可辩护的训练数据的买家来说，这是一个关键的差异化因素。
Marketplace
Dataset details
Geographic coverage
Global
Time range
2020–Present
Update frequency
Periodic
Delivery
S3 bucket
Formats
DICOM, CSV, JSON
License
One-time license for development, training, and validation of diagnostic AI algorithms. Usage restrictions apply regarding redistribution and commercialization of raw data.
Personal data
Contains PII
Indicative estimate, derived from public signals — not a quote, not contractual, and not agreed with the company. Is this your company? Correct it.
This dataset's value is driven by its regulatory-grade quality from clinical trials and its application in the rapidly growing AI-Powered Diagnostic Imaging market. The complexity of sourcing and the EU MDR compliance increase its premium.
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Eclevar API-Accessible — a Moderate api-accessible dataset (Multimodal modality) in the healthcare domain. Primary AI use-case: RAG. Market signal: Global Medical Device CRO Market = $7.75 billion in 2023, CAGR 8.95% (2024-2030) (source: Grand View Research). Investment score 47.5/100 (confidence 0.42). Recommended action: License.
From the marketplace
Explore live data opportunities
Gefip — 监管记录数据集商机
View opportunity →工业Lancey — 工业传感器数据集机会
View opportunity →医疗保健Ecential Robotics — 传感器遥测数据集机会
View opportunity →